Recombinant R. sanguineus Evasin-1 Fc Chimera Protein, CF

Recombinant R.sanguineus Evasin‑1 Fc Chimera (Catalog # 10016-EV) inhibitsRecombinant Human CCL‑3/MIP‑1 alpha -induced chemotaxis of BaF3 mouse pro B cellstransfected with human CCR5. The ED50 for this effect is 0.2‑1.2 μg/mL.

• Reactivity: I
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant R. sanguineus Evasin-1 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit CCL3/MIP-1 alpha -induced chemotaxis of BaF3 mouse pro‑B cells transfected with human CCR5. The ED₅₀ for this effect is 0.2-1.2 μg/mL
• Source: Human embryonic kidney cell, HEK293-derived r. sanguineus Evasin-1 protein
  

  Human IgG1 (Met-Asp-Pro100 - Lys330)	IEGR	R. sanguineus Evasin-1 (Glu21-Asn114) Accession # P0C8E7.1
  N-terminus		C-terminus

• Accession #: P0C8E7.1
• N-terminal Sequence: Met-Asp-Pro100
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Theoretical MW: 37 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 40-61 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage:
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant R. sanguineus Evasin-1 Fc Chimera Protein, CF

• Evasin-1

Background

Evasin-1 is a highly selective chemokine-binding protein isolated from tick saliva. The cDNA of tick Evasin-1 encodes a 114 amino acid (aa) precursor, which include a 20 aa signal peptide and the 94 aa mature protein (1). Ticks are blood sucking parasites that secrete a wide variety of immunomodulatory proteins to evade the host immune response. The saliva isolated from Ticks has shown chemokine neutralization activity. A group of proteins contributing to this activity have been identified as chemokine-binding proteins (CHPBs) and named as Evasins (1-3). Evasin-1 shows high affinity binding to a very limited set of three highly homologous CC chemokines: CCL3, CCL4 and CCL18 (1). Since it is a small molecule, Evasin-1 may be therapeutically useful as novel anti-inflammatory agent.

1. Frauenschuh, A. et al. (2007) J. Biol. Chem. 282:27250.
2. Deruaz, M. et al. (2008) J. Exp. Med. 205:2019.
3. Deruaz, M. et al. (2013) FEBS J. 280:4876.

Bioinformatics

• Uniprot:
  • P0C8E7.1()